Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now? The analyst supported the optimistic rating with the company’s growth potential and the stability of its financial prospects, citing the recent success ...

Key Takeaways Halozyme will report Q3 2025 earnings on Nov. 3, with estimates pegged at $336.9M for sales and $1.62 for EPS.Royalty gains from Roche, J&J and argenx are expected to lift Halozyme's third-quarter top line.The Elektrofi deal broadens Halozyme's drug delivery tech and reaffirms its 2025 revenue outlook.Halozyme Therapeutics (HALO) is scheduled to report third-quarter 2025 results on Nov. 3, after market close. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged a ...

The market expects Halozyme Therapeutics (HALO) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 3, might help the stock move higher if these key num ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been around six months since my previous Halozyme (NASDAQ: HALO ) article , where I defended the company’s growth designation thanks to an impressive Q1 earnings with a 35% increase in revenue, 54% net income growth, and management raising theirHe ...

Accessibility StatementSkip Navigation Tram BuiVP, Investor Relations and Corporate Communications609-333-7668[email protected] Sydney CharltonTeneo917-972-8407[email protected] SOURCE Halozyme Therapeutics, Inc. SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, Nove ...

公司近期盈利表现 - 公司在最近两个季度持续超出盈利预期，平均超出幅度达21.02% [1] - 最近一个季度，公司每股收益为1.54美元，超出市场预期的1.23美元，超出幅度为25.20% [2] - 上一季度，公司每股收益为1.11美元，超出市场预期的0.95美元，超出幅度为16.84% [2] 未来盈利预测与指标 - 近期市场对公司的盈利预测正在上调 [5] - 公司目前的Zacks盈利ESP为+1.48%，表明分析师近期对其盈利前景转为乐观 [8] - 研究显示，当盈利ESP为正且Zacks评级为持有或更好时，公司有近70%的概率会再次超出盈利预期 [6] - 盈利ESP指标通过比较最准确估计与市场一致预期得出，反映了分析师在财报发布前基于最新信息所做的修正 [7] 投资分析框架 - 盈利ESP指标与Zacks评级结合使用，公司当前Zacks评级为买入 [8] - 该分析框架旨在提高在财报发布前识别投资机会的成功概率 [10]

公司核心增长动力 - 公司2025年实现稳健增长，主要受投资者对其用于皮下给药的新型药物递送技术ENHANZE的信心增强所驱动 [1] - 公司营收主要来自与大型制药公司就ENHANZE技术达成的合作协议，包括已上市药物的销售分成、里程碑付款和年度许可费 [2] - 目前有八款基于ENHANZE技术的合作药物已上市，包括强生的Darzalex皮下制剂和罗氏的Phesgo [2] 业务拓展与收购 - 公司于2025年第四季度预计完成对Elektrofi公司的收购，以加强其药物递送能力并拓宽技术平台 [4][5] - 根据协议，公司将支付7.5亿美元的前期款项，并为三个独立产品的监管批准分别支付最高5000万美元的里程碑付款 [5] - 此次收购旨在使业务多元化，预计从2030年开始产生许可费收入，并支持收入持续增长至2040年 [4][5] 财务表现与预期 - 2025年上半年，公司特许权使用费收入同比增长52.3%，达到3.738亿美元 [6] - 总收入增长由罗氏的Phesgo、强生的Darzalex SC以及argenx的Vyvgart Hytrulo等药物带来的更高特许权使用费驱动 [7] - 公司预计2025年总收入将在12.8亿美元至13.6亿美元之间，较2024年增长26%至33% [7] - 公司两款自有商业产品Hylenex和Xyosted也为2025年上半年的收入增长做出了贡献 [8] 股价与估值 - 年初至今，公司股价上涨38.8%，同期行业涨幅为8.2%，表现优于行业和标普500指数 [10][12] - 按市销率计算，公司股票当前交易价格为过去12个月销售额的6.99倍，高于行业的2.23倍，但低于其五年均值8.76倍 [14] - 市场对2025年每股收益的共识估计稳定在6.18美元，对2026年的每股收益预期从7.57美元上调至7.61美元 [15]

Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty ImagesSOPA Images/LightRocket via Getty ImagesHalozyme Therapeutics (HALO) stock could be a solid choice to leverage the current momentum. Why? Because it offers strong margins, a low-debt capital structure, reasonable valuation, and strong momentum. Here are some key data points.Revenue Growth: Halozyme Therapeutics experienced revenue growth of 35.0% LTM and 35.5% over the last 3 years’ average.Long-Term Profitability: Approximately 44. ...

Key Takeaways Halozyme will acquire Elektrofi for $750M plus up to $150M in milestone payments.The deal adds Elektrofi's Hypercon technology, expanding Halozyme's delivery capabilities.HALO reaffirmed its 2025 revenue outlook, expecting $1.28B-$1.36B in total revenues.Halozyme Therapeutics (HALO) has collaboration deals related to its ENHANZE technology with large pharma companies that use the technology for the development of subcutaneous (“SC”) formulations of their various approved drugs. These deals gen ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to $90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025. Benchmark’s revised price target depends on the biotechnology company’s projected 2025 revenues being 8.5 times higher. The firm also reported that Mer ...